Prognostic factors for anti-cancer therapy efficiency

Cover Page

Cite item

Full Text

Abstract

Aim. To investigate the relationship between blood plasma biochemical indicators in patients with solid tumors before a treatment and after the first course of chemotherapy with objective treatment response. Methods. Blood plasma samples taken from 14 patients with cancer relapse were studied before the treatment and after the first course of specific chemotherapy (carboplatin, methotrexate, vinblastine in patients with urine bladder cancer and irinotecan, leukovorin and fluorouracil in patients with colorectal cancer). The first group included patients with colorectal cancer relapse (males - 3, females - 4) aged 57-62 years. The second group included patients with urine bladder cancer relapse (males - 5, females - 2) aged 48-64 years. Free radical activity and protein oxidative modification, as well as endogenous intoxication and major mineral and trace elements levels were studied. Results. When achieving the objective chemotherapy effect in patients after the first treatment course, an increase of alpha-1 globulin and gamma globulin level, as well as an increase of phosphorus, zinc, lithium and iron blood plasma level was observed. In case of following disease progression, the opposite dynamics of above-mentioned indicators was revealed. In patients with good objective effect of polychemotherapy after the first treatment course, a significant increase of endogenous intoxication and blood plasma free radical activity decrease were observed. If the following tumor progression was observed, the tendency of blood plasma free radical activity increase, accompanied by the total protein oxidative modification activation, was revealed after the first treatment course. Conclusion. The increase of alpha-1 and gamma globulin levels, as well as an increase of phosphorus level in blood plasma after the first course of polychemotherapy can be used as prognostic factors of anticancer therapy efficiency. High level of endogenous intoxication as well as an increase of copper, iron, zinc and lithium blood plasma concentrations can be applied as the additional markers.

About the authors

E I Erlykina

Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia

T V Kopytova

Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia

A V Alyasova

Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia

I G Terentiev

Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia

T N Gorshkova

Volga District Medical Centre, Nizhny Novgorod, Russia

V G Pimenov

G.G. Devyatykh Institute of Chemistry of High-Purity Substances, Nizhny Novgorod, Russia

I L Evdokimov

G.G. Devyatykh Institute of Chemistry of High-Purity Substances, Nizhny Novgorod, Russia

L M Obukhova

Nizhny Novgorod State Medical Academy, Nizhny Novgorod, Russia

Email: ObuhovaLM@yandex.ru

References

  1. Блохин Ю.Д. Фенотип множественной лекарственной устойчивости опухолевых клеток, обусловленный нарушением программы клеточной гибели // Вестн. РАМН. - 2004. - №12. - С. 16-20.
  2. Дубинина Е.Е. Продукты метаболизма кислорода в функциональной активности клеток. Жизнь и смерть, созидание и разрушение // СПб.: Медицинская пресса, 2006. - 400 с.
  3. Дубинина Е.И., Бурмистров С.О., Ходов Д.А., Поротов И.Г. Окислительная модификация белков сыворотки крови человека, метод её определения // Вопр. мед. хим. - 1995. - Т. 41, №1. - С. 24-25.
  4. Копытова Т.В., Добротина Н.А., Химкина Л.Н., Ларина Т.Н. Некоторые подходы к лабораторной диагностике эндоинтоксикации при хронических дерматозах // Клин. лаб. диагн. - 2000. - №1. - С. 18-20.
  5. Малахова М.Я. Эндогенная интоксикация как отражение компенсаторной перестройки обменных процессов в организме // Эффер. терап. - 2000. - Т. 6, №4. - С. 3-14.
  6. Орлов Д.С., Носарева О.Л., Коновалова Е.В. и др. Содержание гидроксильного радикала и фракций глутатиона в опухолевых клетках линии Jurkat и лимфоцитах крови // Соврем. наукоёмкие технол. - 2012. - №7. - С. 58-59.
  7. Руководство по химиотерапии опухолевых заболеваний / Под ред. Н.И. Переводчиковой. 2-е изд., доп. - M.: Практическая медицина, 2005. - 365 с.
  8. Apetoh L., Ghiringhelli F., Tesniere A. et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy // Nat. Med. - 2007. - Vol. 13,N 9. - P. 1050-1059.
  9. Aschele C., Lonardi S., Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer // Cancer Treat Rev. - 2002. - Vol. 28, N 1. - Р. 27-47.
  10. Joshi M.B., Shirota Y., Danenberg K.D. et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer // Clin. Cancer Res. - 2005. - Vol. 11, N 6. - Р. 2215-2221.
  11. Lake R.A., Robinson B.W.S. Immunotherapy and chemotherapy- a practical partnership // Nature Reviews. Cancer. - 2005. - Vol. 5. - P. 397-405.
  12. Libra M., Navolanic P.M., Talamini R. et al. Thymidylate synthetase mRNA levels are increased in liver metastases of colorectal cancer patients resistant to fluoropyrimidine-based chemotherapy // BMC Cancer. - 2004. - Vol. 4,N 1. - Р. 11-17.
  13. Mir M.M., Dar N.A., Malik M.A. et al. Studies on association between Copper excess, Zinc deficiency and P53 mutations in esophageal squamous cell carcinoma from Kashmir valley, India - a high risk area // Intern. J. of Health Sciences. - Vol. 1,N 1. - 2007. - Р. 35-41.
  14. Obeid M., Tesniere A., Ghiringhelli F. et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. - Nat. Med. - 2007. - Vol. 13,N 10. - Р. 54-61.
  15. Richardson D.R., Kalinowski D.S., Lau S. et al. Canсer cell iron metabolism and the development of potent iron chelators as anti-tumor agents // Biochim. Biophys. Acta. - 2009. - Vol. 1790,N 7. - P. 702-717.

© 2013 Erlykina E.I., Kopytova T.V., Alyasova A.V., Terentiev I.G., Gorshkova T.N., Pimenov V.G., Evdokimov I.L., Obukhova L.M.

Creative Commons License

This work is licensed
under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.




This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies